Jazz On Track With Q4 EU Filing for Leukemia Treatment Vyxeos
Executive Summary
As European regulators this week consider whether to fast-track the eventual regulatory review of Jazz Pharmaceuticals’ treatment for acute myeloid leukemia, the company says it is on track to file for EU regulatory approval this year.
You may also be interested in...
Half Of All EU Fast-Track Requests Fail; AZ’s Imfinzi Among Latest
The European Medicines Agency recently denied AstraZeneca’s pre-filing request for accelerated assessment of Imfinzi in Stage III NSCLC, an indication the company is hoping to make its own. It’ll be no consolation that the EMA this year seems to have rejected as many fast-track requests as it has granted.
Sanofi Is Aiming For European Accelerated Assessment For Sleeping Sickness Drug
Sanofi will this week learn whether fexinidazole, the drug the company is developing for sleeping sickness, will be evaluated quickly once it files for approval. The European Medicines Agency’s CHMP is considering this week whether to grant the company’s request for accelerated assessment.
Keeping Track: US FDA Approvals Of Mavyret, Idhifa, Vyxeos Headline Week Of Breakthroughs, Hematology And Hematology BTDs
The latest drug development news and highlights from our FDA Performance Tracker.